



|  |  |                           |
|--|--|---------------------------|
| <b>External assessment centre (EAC) representatives present:</b> | • Tosin Oladapo, Health Technology Assessment Analyst  | • Present for all items   |
|  | • Rebecca Brookfield, Health Technology Assessment Analyst   | • Present for all items   |
|  | • Ying-Ying Wang, Health Technology Assessment Analyst   | • Present for all items   |
|  | • Izabela Syrek, Administrator   | • Present for all items   |
|  | • Ms Megan Dale, Senior Researcher, Cedar EAC  | • Present for items 1-8   |
|  | • Miss Edyta Ryczek, Healthcare Scientist, Cedar EAC   | • Present for items 1-8   |
|  | • Dr Micheal Drinnan, Head of Clinical Engineering, Northern Medical Physics & Clinical Engineering, Newcastle upon Tyne Hospitals NHS Foundation Trust (NuTH) | • Present for items 1-9   |
| <b>Expert advisers present</b>                                   | • Dr Andrew Sims, Director, Newcastle Consortium   | • Present for items 16-20 |
|  | • Mrs Helen Cole, Head of Service – Clinical Scientist, Newcastle Consortium   | • Present for items 16-20 |
|  | • Mr Nicholas Fletcher, Urology Surgical Care Practitioner, Salford Royal Hospital, Salford Royal NHS Foundation Trust   | • Present for items 1-8   |
|  | • Mr Ased Ali, Consultant Urological Surgeon, Mid Yorkshire Hospital NHS Trust   | • Present for items 1-8   |
|  | • Ms Mahreen Pakzad, Consultant Urological Surgeon, University College of London Hospital and the National Hospital for Neurology and Neurosurgery             | • Present for items 1-8   |
| <b>Non-public present:</b>                                       | • Mr Neil Barber, Consultant Urological Surgeon, Frimley Park Hospital, Frimley Health NHS Foundation Trust  | • Present for items 16-20 |
|  | • Mr Richard Hindley, Consultant Urologist, Basingstoke North Hampshire Hospital, Hampshire Hospitals NHS Foundation Trust                                     | • Present for items 16-20 |
|  | • Katie Wyart, Medical Technology Implementation Manager, Adoption and Impact Team, NICE   | • Present for all items   |
|  | • Emilene Coventry, Editorial Adviser, Publishing Team, NICE   | • Present for all items   |
|  | • Helen Crosbie, Public Involvement Adviser, Public Involvement Programme, NICE  | • Present for all items   |
|  | • Katy Harrison, Scientific Adviser, Science Policy and Research Programme, NICE   | • Present for all items   |
|  | • Helen Gallo, Senior Analyst, Interventional Procedures Programme Team, NICE  | • Present for all items   |
|  | • Chris Chesters, Senior Scientific Adviser, NICE Scientific Advice Team   | • Present for items 1-8   |

- Maroulla Whiteley, Business Analyst, Resource Impact Assessment Team • Present for items 1-8
- Ian Mather, Senior Business Analyst (Accountant), Resource Impact Assessment Team • Present for items 1-8
- Naja Warrer Iversen, Director, Center of Economy and Negotiations, Danish Center for Social Research • Present for items 1-8, 10-14, 16-20
- Morten Palle, Head of Division, Center of Health Innovation, Danish Center for Social Research • Present for items 1-8, 10-14, 16-20
- Mirja Kløjgaard, Chief Adviser and Team Leader, Center of Economy and Negotiations, Danish Center for Social Research • Present for items 1-8, 10-14, 16-20
- Maj-Britt Juhl Poulsen, Chief Adviser and Team Leader, Center of Health Innovation, Danish Center for Social Research • Present for items 1-8, 10-14, 16-20
- Thomas Birk Andersen, Chief Adviser, Center of Health Innovation, Danish Center for Social Research • Present for items 1-8, 10-14, 16-20
- Emilie Sophie Frank, Adviser, Center of Health Innovation, Danish Center for Social Research • Present for items 1-8, 10-14, 16-20
- Rikke Lyng Storgaard, Director for Welfare and Health at Oxford Research, Danish Center for Social Research • Present for items 1-8, 10-14, 16-20
- Thomas Nymann Nielsen, Chief Adviser and Team Leader, Center of Economy and Negotiations • Present for items 1-8, 10-14, 16-20
- Sanne Nørgaard Laursen, Senior Adviser, Center of Economy and Negotiations • Present for items 1-8, 10-14, 16-20

### **Introduction to the meeting**

1. The chair welcomed all members of the committee and other attendees present to the meeting.

### **News and announcements**

2. The chair offered news and announcements and noted committee members who had given apologies for the meeting.

### **Minutes of previous meeting**

3. The committee agreed the minutes from the 15<sup>th</sup> November 2019 committee meeting.

## **MT417 Axonics sacral neuromodulation system for bladder control in people with symptoms of overactive bladder**

### **Part 1 – Open session**

4. The chair welcomed the invited experts, external assessment centre representatives and company representatives from Axonics Modulation Technologies. The chair then explained the code of conduct to the members of the public observing the meeting.
5. The chair asked all committee members, experts, NICE staff and observers to declare any relevant interests in relation to the technology being considered.
  - Prof Shaheen Hamdy declared an indirect financial professional interest ahead of the meeting as he is a co-applicant/co-investigator of an EME/MRC funded project; SubSONIC study: “Randomised double-blind efficacy and mechanism study of sub-sensory sacral (optimised) neuromodulation in adults with faecal incontinence”. The study is using the Medtronic Interstim II Model 3058.
    - It was agreed that his declarations would not prevent Prof Hamdy from participating in this section of the meeting.
  - Mr Nicholas Fletcher declared a direct financial interest ahead of the meeting as he received a fee for teaching session for Medtronic on PNE under LA in clinic setting.
    - It was agreed that his declarations would not prevent Mr Fletcher from participating in this section of the meeting.
  - Ms Mahreen Pakzad declared a direct non-financial professional interest ahead of the meeting as she is Chief Investigator of a case series for treatment of female urinary retention patients with the Axonics device. She is also Principal Investigator in company sponsored clinical trial. Trial is no longer recruiting and has just published its one-year results. (ARTISAN)
    - It was agreed that her declarations would not prevent Ms Pakzad from participating in this section of the meeting.

No other interests were declared.

6. The committee was asked if there were any specific equality issues to consider in relation to the technology being considered.
7. The topic was introduced by Dr Jai Patel and Prof Allan Wailoo with Mr Nicholas Fletcher, Mr Ased Ali and Ms Mahreen Pakzad providing expert advice.
8. The chair thanked the experts, external assessment centre representatives, members of the public and company representatives for their attendance and they left the meeting.

## **Part 2 – Closed session**

9. The committee then proposed draft recommendations on the technology and these recommendations were reached by consensus.

### **MT273 PneuX for preventing ventilator-associated pneumonia**

#### **Part 1 – Open session**

10. The chair then explained the code of conduct to the members of the public observing the meeting.
11. The chair asked all committee members, experts, NICE staff and observers to declare any relevant interests in relation to the technology being considered.
  - Dr Mike Burrows declared a non-financial professional interest ahead of the meeting as his place of work - The ASN Network has supported the NHS adoption of PneuX.
    - It was agreed that his declarations would not prevent Dr Burrows from participating in this section of the meeting.

No other interests were declared.

12. The committee was asked if there were any specific equality issues to consider in relation to the technology being considered.
13. The topic was introduced by Lizzy Latimer, Health Technology Assessment Adviser.
14. The chair thanked the members of the public for their attendance and they left the meeting.

#### **Part 2 – Closed session**

15. The committee then proposed final recommendations on the technology and these recommendations were reached by consensus.

### **MT413 Rezum for treating benign prostatic hyperplasia**

#### **Part 1 – Open session**

16. The chair welcomed the invited experts, external assessment centre representatives and company representatives from Boston Scientific. The chair then explained the code of conduct to the members of the public observing the meeting.

17. The chair asked all committee members, experts, NICE staff and observers to declare any relevant interests in relation to the technology being considered.

- Mr Neil Barber declared a direct financial interest ahead of the meeting as he received a proctorship fee and travel support from Teleflex / Neotract – providers of competitor products. He also received travel support from Procept-Biorobotics who provide Aquabaltion therapy of the prostate.
  - It was agreed that his declarations would not prevent Mr Barber from participating in this section of the meeting.
- Mr Richard Hindley declared a direct financial interest ahead of the meeting as he received a consultancy fee from Boston Scientific for teaching and training. Mr Hindley has been asked to give multiple presentations at meetings. In addition, Mr Hindley's urology group partnership has a number of websites including rezum.co.uk which is used for raising awareness, information and marketing.
  - It was agreed that his declarations would not prevent Mr Hindley from participating in this section of the meeting.

No other interests were declared.

18. The committee was asked if there were any specific equality issues to consider in relation to the technology being considered.

19. The topic was introduced by Mr Chris Hudson and Dr David Partridge with Mr Neil Barber and Mr Richard Hindley providing expert advice.

20. The chair thanked the experts, external assessment centre representatives, members of the public and company representatives for their attendance and they left the meeting.

## **Part 2 – Closed session**

21. The committee then proposed final recommendations on the technology and these recommendations were reached by consensus.

### **Date of the next meeting**

22. The next meeting of the medical technologies advisory committee will be held on Friday 21<sup>st</sup> February 2020 and will start promptly at 10:00am. The meeting will be held at the NICE Manchester offices, Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BT.